Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saladax Biomedical has signed a diagnostic agreement with Eilaf Pharma for My5-FU diagnostic test in Egypt and throughout the Middle East North African (MENA) region.
Subscribe to our email newsletter
The test will measure the levels of an anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients and allows oncologists to determine the optimal dose of 5-FU for each patient.
Saladax chief marketing officer Adrienne Choma said, "We’re happy to be working with Eilaf to provide patients with colorectal cancer in the region a new option to help maximize the therapeutic effect of their chemotherapy."
Eilaf is a new joint stock health care company that promotes products to market- leading positions in Egypt and the MENA region.